Sharekhan

Indegene Ltd

Fri 7/11/2025,15:59:17 | NSE : INDGN

₹ 523.10-7.05 (-1.33%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 527.00

Previous Close

₹ 530.15

Volume

511121

Mkt Cap ( Rs. Cr)

₹12558.54

High

₹ 528.65

Low

₹ 507.70

52 Week High

₹ 735.00

52 Week Low

₹ 499.00

Book Value Per Share

₹ 98.31

Dividend Yield

0.00

Face Value

₹ 2.00

What’s Your Call?

Collective community sentiment on Indegene Ltd

Your Vote -

Buy

80.00%

Hold

0.00%

Sell

20.00%

80.00%

5 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

523.10

2

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

2

Option Chain

Analyzes market sentiment, predicts Indegene Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Indegene - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    3 Nov 2025, 12:54PM Intimation of Earnings Call Transcript for Q2 FY26
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    3 Nov 2025, 12:53PM Indegene Limited has informed the Exchange about Transcript
  • Indegene - General Updates

    1 Nov 2025, 7:53PM Intimation of opening of trading window
  • Indegene - Copy of Newspaper Publication

    1 Nov 2025, 7:45PM Newspaper Advertisement-Financial Results for quarter ended September 30, 2025
  • Indegene - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    31 Oct 2025, 12:00PM Audio Recording of the Q2FY26 earnings call
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    31 Oct 2025, 11:49AM Indegene Limited has informed the Exchange about Link of Recording
  • Indegene - Monitoring Agency Report

    31 Oct 2025, 11:45AM Monetary Agency Report for the quarter ended September 30,2025
  • Indegene - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

    31 Oct 2025, 11:41AM Monetary Agency Report for the quarter ended September 30,2025
  • Indegene Q2 net profit up 33.71% at Rs 59.90 cr

    30 Oct 2025, 10:01PM The company reported standalone net profit of Rs 59.90 crore for the quarter ended September 30, 2025 as compared to Rs 44.80 crore in the same period
  • Indegene - Disclosure Under SEBI (LODR) Regulations, 2015 - Investment In Wholly Owned Subsidiary

    30 Oct 2025, 9:59PM Disclosure under SEBI (LODR) Regulations, 2015 - Investment in wholly owned subsidiary
  • Indegene - Announcement under Regulation 30 (LODR)-Investor Presentation

    30 Oct 2025, 9:49PM Analyst presentation and fact sheet - financial results for the quarter ended September 30, 2025
  • Indegene - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    30 Oct 2025, 9:44PM Press Release
  • Indegene - Disclosure Under Regulation 30 Of SEBI(LODR) Regulations, 2015 - Intimation Of Grant

    30 Oct 2025, 9:35PM Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - Intimation of Grant
  • Indegene - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    30 Oct 2025, 9:22PM Allotment under ESOP 2020 Plan & RSU 2020 Plan
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    30 Oct 2025, 9:11PM Indegene Limited has informed the Exchange about Presentation
  • Indegene - Press Release

    30 Oct 2025, 9:02PM Indegene Limited has informed the Exchange regarding a press release dated October 30, 2025, titled ""Indegene Continues Strong Momentum with 17% YoY
  • Indegene - General Updates

    30 Oct 2025, 8:45PM Indegene Limited has informed the Exchange about Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulati
  • Indegene - ESOP/ESOS/ESPS

    30 Oct 2025, 8:38PM Indegene Limited has informed the Exchange regarding Grant of 480117 Options.
  • Indegene - ESOP/ESOS/ESPS

    30 Oct 2025, 8:25PM Indegene Limited has informed the Exchange regarding Allotment of 151651 Shares.
  • Indegene - Outcome Of Board Meeting - Q2FY26 Results

    30 Oct 2025, 8:20PM Outcome of Board Meeting - Q2FY26 Results
  • Indegene - Outcome of Board Meeting

    30 Oct 2025, 7:51PM Indegene Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
  • Indegene - Board Meeting Outcome for Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requireme

    30 Oct 2025, 7:46PM Outcome of Board Meeting
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    24 Oct 2025, 8:31PM Indegene Limited has informed the Exchange about Schedule of meet - Update
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    23 Oct 2025, 3:18PM Indegene Limited has informed the Exchange about Schedule of meet
  • Indegene - Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And

    23 Oct 2025, 2:55PM Indegene Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2025 ,inter alia, to consider and approve
  • Indegene has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2025

    17 Oct 2025, 6:40PM As of September 2025, 100.00% owned by Public. <p align=justify> Institutional holds 18.25% (Insurance Companies 0.01%) and Non-Institutional holds 81
  • Indegene - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    17 Oct 2025, 10:54AM Press Release
  • Indegene - Press Release

    17 Oct 2025, 10:52AM Indegene Limited has informed the Exchange regarding a press release dated October 17, 2025, titled ""Indegene Strengthens Consulting Practice to Acce
  • Indegene - Acquisition

    17 Oct 2025, 10:38AM Indegene Limited has informed the Exchange about Acquisition
  • Indegene - Announcement under Regulation 30 (LODR)-Acquisition

    17 Oct 2025, 10:33AM Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015- Acquisition
  • Indegene - Reg. 34 (1) Annual Report.

    16 Oct 2025, 10:17PM Annual Report for FY 2024-25
  • Indegene - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    9 Oct 2025, 3:13PM Indegene Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Indegene - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    9 Oct 2025, 3:11PM Certification under Regulation 74(5) of SEBI(Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2025
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    8 Oct 2025, 4:53PM Indegene Limited has informed the Exchange about Transcript
  • Indegene - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    8 Oct 2025, 4:49PM Transcript of the conference call of the Analysts / Investors meet.
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    7 Oct 2025, 8:55AM Indegene Limited has informed the Exchange about Link of Recording
  • Indegene - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    7 Oct 2025, 8:58AM Audio Recording of the Investor / Analyst Meeting
  • Indegene - Investor Presentation

    2 Oct 2025, 9:59PM Indegene Limited has informed the Exchange about Investor Presentation
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    1 Oct 2025, 2:34PM Indegene Limited has informed the Exchange about Schedule of meet
  • Indegene - Press Release

    1 Oct 2025, 2:29PM Indegene Limited has informed the Exchange regarding a press release dated October 01, 2025, titled ""Indegene Announces Acquisition of BioPharm to Ex
  • Indegene - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    1 Oct 2025, 2:29PM Press Release
  • Indegene - Acquisition

    1 Oct 2025, 2:25PM Indegene Limited has informed the Exchange about Acquisition
  • Indegene - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    1 Oct 2025, 2:35PM Intimation of Schedule of Investors / Analysts meeting under the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015\r\n
  • Indegene - Announcement under Regulation 30 (LODR)-Acquisition

    1 Oct 2025, 2:26PM Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations,2015
  • Indegene - Trading Window

    26 Sep 2025, 5:10PM Indegene Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
  • Indegene - Press Release

    24 Sep 2025, 5:31PM Indegene Limited has informed the Exchange regarding a press release dated September 24, 2025, titled ""Life Sciences Leaders Reimagine AI-Powered Com
  • Indegene - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    24 Sep 2025, 5:27PM Press Release
  • Indegene - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    19 Sep 2025, 5:33PM Press Release
  • Indegene - Press Release

    19 Sep 2025, 5:32PM Indegene Limited has informed the Exchange regarding a press release dated September 19, 2025, titled ""Datavant and Indegene Partner to Power More Ef
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    1 Sep 2025, 7:23PM Indegene Limited has informed the Exchange about Schedule of meet
  • Indegene - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    1 Sep 2025, 7:20PM Intimation of Schedule of Investors / Analysts meetings
  • Indegene - ESOP/ESOS/ESPS

    21 Aug 2025, 8:00PM Indegene Limited has informed the Exchange regarding Allotment of 379 Shares.
  • Indegene - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    21 Aug 2025, 8:00PM Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
  • Indegene - Press Release

    19 Aug 2025, 1:54PM Indegene Limited has informed the Exchange regarding a press release dated August 19, 2025, titled ""Indegene Wins Gold for Gamified Learning and Deve
  • Indegene - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    19 Aug 2025, 1:51PM Press Release
  • Indegene - Shareholders meeting

    13 Aug 2025, 5:36PM Indegene Limited has submitted the Exchange voting results and a copy Scrutinizer's report on Postal Ballot
  • Indegene - Shareholder Meeting / Postal Ballot-Scrutinizer\s Report

    13 Aug 2025, 5:30PM Voting Results of Postal Ballot along with Scrutinizer's Report
  • Indegene - Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot

    13 Aug 2025, 5:28PM Voting Results of Postal Ballot along with Scrutinizer's Report
  • Indegene Ltd

    9 Oct 2025 , 9:01AM Indegene : The company is ramping up its US strategy, betting that pricing pressures under the Trump administration will accelerate the pharmaceutical industry’s shift toward digital-first, non-personal marketing. The company’s recent $104 million acquisition of BioPharm Communications, a Pennsylvania-based adtech firm, is central to this pivot. BioPharm acquisition from Omnicom Group gives Indegene access to a proprietary database of more than 15 million physician engagements and around 300 million exposure events, enabling hyper-targeted campaigns for top pharma clients.
  • Indegene Ltd

    4 Jun 2025 , 9:49AM Indegene: Carlyle Group is set to exit a 10.2% stake in the company for at least Rs 1,420 crore. The floor price is Rs 580 per share, which is a 6% discount from the current market price.
  • Indegene

    20 Mar 2025 , 11:34AM The company launched a new centre In London to expand in Europe. This aligns with the company's long-term growth strategy in Europe, reiterating its commitment to enable life sciences clients in the region to be future-ready.
  • Indegene

    3 Dec 2024 , 11:16AM Global private equity firm Carlyle-backed CA Dawn Investments likely to divest 2.9% stake in Indegene via block deal at Rs.615 per share. As per media sources, the sale could raise approximately Rs 470 crore, based on the offered floor price.
  • Indegene announces strategic collaboration with Microsoft

    11 Jul 2024 , 11:38AM Indegene collaborates with Microsoft to help life sciences companies scale up Generative AI adoption

Key fundamentals

Evaluate the intrinsic value of Indegene Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 1888.2 953.8 795.3 650 442.2
Liabilities 1888.2 953.8 795.3 650 442.2
Equity 47.9 44.4 44.3 0.4 0.3
Gross Profit 180.5 168 177.9 168.7 150.4
Net Profit 181.3 137.9 130.2 132.7 133.4
Cash From Operating Activities 129 176.2 81.9 38.2 54.6
NPM(%) 16.57 13.18 12.94 15.85 26.1
Revenue 1093.6 1045.6 1005.7 836.7 511
Expenses 913.1 877.6 827.8 668 360.6
ROE(%) 7.68 5.84 5.51 5.62 5.65

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
13 Jun 2025 2 100 0 571.5

Peers

Other companies within the same industry or sector that are comparable to Indegene Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Visagar Polytex Ltd 0.78 -1.27 0.00 15312.65 -6.09 0.00
India Motor Parts and Accessories Ltd 1069.30 2.58 15.49 652.89 670.43 2.81
Madhya Pradesh Today Media Ltd 38.00 -3.80 5.44 238.97 69.80 0.00
Hathway Cable and Datacom Ltd 13.34 0.08 24.25 92602.78 26.13 0.00

Company Info

Our Company was incorporated as `Indegene Lifesystems Private Limited' at Ahmedabad, Gujarat, as a private limited company, under the Companies Act, 1956, pursuant to a certificate of incorporation dated October 16, 1998, issued by the Registrar of Companies, Gujarat, Dadra & Nagar Haveli at Ahmedabad. Thereafter, the registered office of our Company was shifted from Gujarat to Karnataka in June 2003, and then, from Karnataka to Maharashtra in May 2014. Further, pursuant to a resolution passed by our Shareholders at the EGM held on February 29, 2016, the name of our Company was changed to `Indegene Private Limited' and a fresh certificate of incorporation was issued by the Registrar of Companies, Maharashtra at Mumbai on May 26, 2016. The name of our Company was changed to better reflect the nature of business undertaken by our Company. Thereafter, the registered office of our Company was shifted from Maharashtra to Karnataka in February 2017. Subsequently, our Company was converted from a private limited company to a public limited company, pursuant to a special resolution passed by our Shareholders at the EGM held on November 7, 2022 and the name of our Company was changed to `Indegene Limited' and a fresh certificate of incorporation was issued to our Company by the RoC, on November 17, 2022.Major events and milestones:2005-Raised funding from Nadathur Holdings & Investments Private Limited-Expanded operations to the USA by incorporating a subsidiary named Indegene, Inc.-Expanded operations to Southeast Asia by incorporating a subsidiary named Indegene Fareast Pte. Ltd. in Singapore2006-Acquisition of Medsn, Inc.1 a company in the USA which is engaged in medical education and marketing business, by one of our Material Subsidiaries, Indegene, Inc.2 through the merger of Medsn Merger Sub, Inc., an erstwhile wholly owned subsidiary of Indegene, Inc. with Medsn, Inc.2007-Expanded our services to include European territory2008-Received BS ISO/IEC 27001:2005 certification for information security management system32009-Received ISO 9001:2000 certification for quality management system42012-Expanded operations to China by incorporating a subsidiary named Indegene Lifesystems Consulting (Shanghai) Co., Ltd.2017-Acquisition of the Encima Group, Inc., a corporation which operates a digital service, marketing automation and analytics services business supporting clients in healthcare, life sciences and other industries by one of our Material Subsidiaries, ILSL Holdings, Inc.2020-Acquisition of DT Associates Research and Consulting Services Limited, a consulting services company in UK supporting clients in healthcare, life sciences and other industries by one of our Material Subsidiaries, ILSL Holdings, Inc.-Launched Indegene Digital Summit, a symposium on digital transformation and customer experience in life sciences2021-Expanded operations to Japan by incorporating a subsidiary named Indegene Japan, LLC-Raised equity funding from CA Dawn Investments and Brighton Park Capital-Received BS ISO/IEC 27701:2019 certification for privacy information management system52022-Acquisition of Medical Marketing Economics, LLC by one of our Material Subsidiaries, ILSL Holdings, Inc. and subsequent merger of Medical Marketing Economics, LLC with Indegene, Inc.-Expanded global operations with new offices in Mexico2023-Acquisition of Cult Health, a company engaged in the business of providing advertising services to parties in the healthcare sector, by one of our Material Subsidiaries, ILSL Holdings, Inc.-Expanded our presence in Europe with the acquisition of Indegene Healthcare Germany GmbH (formerly Sotus 852 GmbH) by our subsidiary, Indegene Ireland Limited-Launched Invisage, an AI-enabled hybrid omnichannel sales and marketing platform2024-Acquisition of Trilogy Writing & Consulting GmbH, a company engaged in providing high-end medical writing to customers that include market-leading pharmaceutical companies, along with three of its wholly owned subsidiaries, by one of our Subsidiaries, Indegene Ireland Limited.-Ranked 167 in The Next 500 India's Largest Emerging Companies by Fortune India

Our Company was incorporated as `Indegene Lifesystems Private Limited' at Ahmedabad, Gujarat, as a private limited company, under the Companies Act, 1956, pursuant to a certificate of incorporation dated October 16, 1998, issued by the Registrar of Companies, Gujarat, Dadra & Nagar Haveli at Ahmedabad. Thereafter, the registered office of our Company was shifted from Gujarat to Karnataka in June 2003, and then, from Karnataka to Maharashtra in May 2014. Further, pursuant to a resolution passed by our Shareholders at the EGM held on February 29, 2016, the name of our Company was changed to `Indegene Private Limited' and a fresh certificate of incorporation was issued by the Registrar of Companies, Maharashtra at Mumbai on May 26, 2016. The name of our Company was changed to better reflect the nature of business undertaken by our Company. Thereafter, the registered office of our Company was shifted from Maharashtra to Karnataka in February 2017. Subsequently, our Company was converted from a private limited company to a public limited company, pursuant to a special resolution passed by our Shareholders at the EGM held on November 7, 2022 and the name of our Company was changed to `Indegene Limited' and a fresh certificate of incorporation was issued to our Company by the RoC, on November 17, 2022.Major events and milestones:2005-Raised funding from Nadathur Holdings & Investments Private Limited-Expanded operations to the USA by incorporating a subsidiary named Indegene, Inc.-Expanded operations to Southeast Asia by incorporating a subsidiary named Indegene Fareast Pte. Ltd. in Singapore2006-Acquisition of Medsn, Inc.1 a company in the USA which is engaged in medical education and marketing business, by one of our Material Subsidiaries, Indegene, Inc.2 through the merger of Medsn Merger Sub, Inc., an erstwhile wholly owned subsidiary of Indegene, Inc. with Medsn, Inc.2007-Expanded our services to include European territory2008-Received BS ISO/IEC 27001:2005 certification for information security management system32009-Received ISO 9001:2000 certification for quality management system42012-Expanded operations to China by incorporating a subsidiary named Indegene Lifesystems Consulting (Shanghai) Co., Ltd.2017-Acquisition of the Encima Group, Inc., a corporation which operates a digital service, marketing automation and analytics services business supporting clients in healthcare, life sciences and other industries by one of our Material Subsidiaries, ILSL Holdings, Inc.2020-Acquisition of DT Associates Research and Consulting Services Limited, a consulting services company in UK supporting clients in healthcare, life sciences and other industries by one of our Material Subsidiaries, ILSL Holdings, Inc.-Launched Indegene Digital Summit, a symposium on digital transformation and customer experience in life sciences2021-Expanded operations to Japan by incorporating a subsidiary named Indegene Japan, LLC-Raised equity funding from CA Dawn Investments and Brighton Park Capital-Received BS ISO/IEC 27701:2019 certification for privacy information management system52022-Acquisition of Medical Marketing Economics, LLC by one of our Material Subsidiaries, ILSL Holdings, Inc. and subsequent merger of Medical Marketing Economics, LLC with Indegene, Inc.-Expanded global operations with new offices in Mexico2023-Acquisition of Cult Health, a company engaged in the business of providing advertising services to parties in the healthcare sector, by one of our Material Subsidiaries, ILSL Holdings, Inc.-Expanded our presence in Europe with the acquisition of Indegene Healthcare Germany GmbH (formerly Sotus 852 GmbH) by our subsidiary, Indegene Ireland Limited-Launched Invisage, an AI-enabled hybrid omnichannel sales and marketing platform2024-Acquisition of Trilogy Writing & Consulting GmbH, a company engaged in providing high-end medical writing to customers that include market-leading pharmaceutical companies, along with three of its wholly owned subsidiaries, by one of our Subsidiaries, Indegene Ireland Limited.-Ranked 167 in The Next 500 India's Largest Emerging Companies by Fortune India

Read More

Parent Organisation

Indegene Ltd.

Founded

16/10/1998

Managing Director

Mr.Manish Gupta

NSE Symbol

INDGNEQ

FAQ

The current price of Indegene Ltd is ₹ 523.10.

The 52-week high for Indegene Ltd is ₹ 528.65 and the 52-week low is ₹ 507.70.

The market capitalization of Indegene Ltd is currently ₹ 12558.54. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Indegene Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Indegene Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Indegene Ltd shares.

The CEO of Indegene Ltd is Mr.Manish Gupta, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT